Can clinical response to cyclosporin in chronic severe asthma be predicted by an in vitro T-lymphocyte proliferation assay?

European Respiratory Journal

Volumn 9, Issue 7, 1996, Pages 1421-1426

  Alexander, A G ^a   Barnes, N C ^b   Kay, A B ^a   Corrigan, C J ^a,c  

^a National Mean and Lung Institute ^*  (United Kingdom)

^b LONDON CHEST HOSPITAL   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

asthma; cyclosporin; glucocorticoid; proliferation assay; T lymphocyte

Indexed keywords

CYCLOSPORIN; DEXAMETHASONE; GLUCOCORTICOID; LECTIN; PHYTOHEMAGGLUTININ; PLACEBO; THYMIDINE; TRITIUM;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; T LYMPHOCYTE;

ASTHMA; CELL DIVISION; CROSS-OVER STUDIES; CYCLOSPORINE; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYTOHEMAGGLUTININS; PREDICTIVE VALUE OF TESTS; T-LYMPHOCYTES;

EID: 0030057157     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.96.09071421     Document Type: Article

References (17)

1. Barnes PJ. A new approach to the treatment of asthma. N Engl J Med 1989; 321: 1517-1527.
2. Carmichael J, Patterson IC, Diaz P, Crompton GK, Kay AB, Grant IWB. Corticosteroid resistance in chronic asthma. BMJ 1981; 282: 1419-1422.
3. Corrigan CJ, Brown PH, Barnes NC, et al. Glucocorticoid resistance in chronic asthma: glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T-cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis 1991; 144: 1016-1025.
4. Corrigan CJ, Brown PH, Barnes NC, Tsai JJ, Frew AJ, Kay AB. Glucocorticoid resistance in chronic asthma: peripheral blood T-lymphocyte activation and a comparison of the T-lymphocyte inhibitory effects of glucocorticoids and cyclosporin A. Am Rev Respir Dis 1991; 144: 1026-1032.
5. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992; 339: 324-328.
6. Corrigan CJ, Kay AB. CD4 T-lymphocyte activation in acute severe asthma: relationship to disease severity and atopic status. Am Rev Respir Dis 1990; 141: 970-977.
7. Corrigan CJ, Haczku A, Gemou-Engesaeth V, et al. CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5: effect of glucocorticoid therapy. Am Rev Respir Dis 1993; 147: 540-547.
8. Haczku A, Alexander AG, Brown P, et al. The effect of dexamethasone, cyclosporin and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma. J Allergy Clin Immunol 1994; 93: 510-519.
9. Pollak R, Dumble LJ, Lazda VA, Maddux MS, Stormoen B, Ward M. Utility of an in vitro immunoassay to guide immunosuppressive therapy. Transplant Proc 1991; 23(1): 1113-1114.
10. Nizankowska E, Soja J, Pinis G, et al. Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J 1995; 8: 1091-1099.
11. Lock SH, Kay AB, Barnes NC. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 1996; 153: 509-514.
12. Stellato C, de Paulis A, Ciccarelli A, et al. Anti-inflammatory effect of cyclosporin A on human skin mast cells. J Invest Dermatol 1992; 98: 800-804.
13. Kita H, Ohnishi T, Okubo Y, Weiler D, Abrams JS, Gleich GJ. Granulocyte/macrophage colony-stimulating factor and interleukin-3 release from human peripheral blood eosinophils and neutrophils. J Exp Med 1991; 174: 745-748.
14. Sigal NH, Dumont FJ. Cyclosporin A, FK-506, and rapamycin: pharmacological probes of lymphocyte signal transduction. Ann Rev Immunol 1992; 10: 519-560.
15. Granelli-Piperno A, Keane M, Steinman RM. Evidence that cyclosporin inhibits cell-mediated immunity primarily at the level of the T-lymphocyte rather than the accessory cell. Transplantation 1988; 46(Suppl.) 53s-60s.
16. Alexander AG, Barnes NC, Kay AB, Corrigan CJ. Clinical response to cyclosporin in chronic severe asthma is associated with reduction in serum soluble interleukin-2 receptor concentrations. Eur Respir J 1995; 8: 574-578.
17. Casolaro V, Spadaro G, Patella V, Marone G. In vivo characterization of the anti-inflammatory effect of cyclosporin A on human basophils. J Immunol 1993; 151: 5563-5573.